服務(wù)熱線：021-64221772，400-920-1772
服務(wù)熱線：021-64221772，400-920-1772
服務(wù)熱線：021-64221772，400-920-1772
abcam是全球最大的抗體供應(yīng)商之一，成立于1998 年，位于英國的劍...
源自寶島臺灣的品牌，主要產(chǎn)品包括Antibodies, Antibody Duos, E...
美天旎公司（Miltenyi Biotec）是德國著名的生物技術(shù)公司，致力于...
RevMAb公司成立于美國，開發(fā)了一種革命性的單克隆抗體生成方法，...
LONZA（龍沙） 瑞士的制藥化工巨頭，龍沙集團(tuán)是一家以生命科學(xué)為...
羅氏診斷致力于開發(fā)和提供從疾病的早期發(fā)現(xiàn)、預(yù)防到診斷、監(jiān)測的...
Raybiotech是一家集生物高科技產(chǎn)品研究、生產(chǎn)、銷售于一體的中外...
德國默克集團(tuán)成功收購美國密理博公司，成立了新的部門——默克密...
英國absolute antibody可以提供如下抗體藥物，可以聯(lián)系一級代理商帛龍生物咨詢訂購：
|
Parental_product |
Product Name |
|
Ab00103-10.0 |
Anti-erbB-2 (Her-2/neu) [4D5-8 (trastuzumab)] |
|
Ab00122-10.0 |
Anti-CD3 epsilon [OKT-3 (muromonab)] |
|
Ab00126-10.0 |
Anti-CD20 [10F381 (rituximab)] |
|
Ab00146-10.0 |
Anti-TNF alpha [cA2 (Infliximab)] |
|
Ab00187-1.1 |
Anti-IL-2R [Daclizumab] |
|
Ab00188-1.1 |
Anti-IL-2R alpha (CD25) [Basiliximab] |
|
Ab00279-1.1 |
Anti-EGFR [C225 (Cetuximab)] |
|
Ab00280-1.1 |
Anti-Tumor associated glycoprotein (TAG) 72 [B72.3 (Satumomab)] |
|
Ab00281-1.6 |
Anti-carcinoembryonic antigen (CEA) [Arcitumomab] |
|
Ab00282-10.0 |
Anti-CD41 [7E3 (Abciximab)] |
|
Ab00283-1.1 |
Anti-CD33 [hP67.6 (Gemtuzumab)] |
|
Ab00296-1.1 |
Anti-C5 [Eculizumab] |
|
Ab00362-1.1 |
Anti-Apolipoprotein A-1 [MabA34] |
|
Ab00447-1.1 |
Anti-CD40L [hu5c8 (Ruplizumab)] |
|
Ab00448-1.1 |
Anti-TNF alpha [CDP 571 (Humicade)] |
|
Ab00449-1.1 |
Anti-alpha 5 beta 1 Integrin [M200 (Volociximab)] |
|
Ab00450-1.1 |
Anti-CD4 [CE9.1 (Clenoliximab)] |
|
Ab00534-1.1 |
Anti-EGFR [Matuzumab] |
|
Ab00535-1.1 |
Anti-CD11a [hu1124 (Efalizumab)] |
|
Ab00536-1.1 |
Anti-OX40L [R4930 (Oxelumab)] |
|
Ab00715-10.0 |
Anti-VEGF [Bevacizumab] |
|
Ab00716-1.1 |
Anti-Integrin alpha 4 [Natalizumab] |
|
Ab00717-10.0 |
Anti-IgE [huMaE11 (Omalizumab)] |
|
Ab00718-10.0 |
Anti-TNF alpha [D2E7 (Adalimumab)] |
|
Ab00722-10.0 |
Anti-IL-12/23 [ABT-874 (Briakinumab)] |
|
Ab00723-10.0 |
Anti-EGFR domain III [h-R3 (Nimotuzumab)] |
|
Ab00726-10.0 |
Anti-CCR4 [KW-0761 (Mogamulizumab)] |
|
Ab00728-10.0 |
Anti-CD22 [hL22 (Epratuzumab)] |
|
Ab00729-10.0 |
Anti-RSV [RSHZ19 (Felvizumab)] |
|
Ab00736-10.0 |
Anti-CD80 [IDEC-114 (Galiximab)] |
|
Ab00737-10.0 |
Anti-IL-6 receptor [rhPM-1 (Tocilizumab)] |
|
Ab00740-10.0 |
Anti-DR5 [PRO95780 (Drozitumab)] |
|
Ab00742-23.0 |
Anti-Tenascin [I-81C6 (Neuradiab)] |
|
Ab00773-10.0 |
Anti-Lymphotoxin alpha [MLTA3698A (Pateclizumab)] |
|
Ab00791-1.1 |
Anti-PD-1 [5C4.B8 (Nivolumab)] |
|
Ab00875-1.1 |
Anti-Podoplanin (MAP tag) [PMab-1] |
|
Ab00958-10.0 |
Anti-CD257 (BAFF) [Tabalumab] |
|
Ab01147-1.1 |
Anti-TAG-72 [Minretumomab (CC49 )] |
